Drug Combination Details
| General Information of the Combination (ID: C33091) | |||||
|---|---|---|---|---|---|
| Name | Metformin NP Info | + | Torin 2 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Pancreatic cancer
[ICD-11: 2C10]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | mTOR | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | KPC3 | CVCL_A9ZK | Mouse pancreatic neoplasm | Mus musculus | ||
| In-vivo Model | To establish the xenograft model, the transplanted KPC adenocarcinoma cell lines (5 * 103 cells) in 30 uL PBS were injected in the gastric lobe of the pancreas of C57BL/6 albino mice. | |||||
| Experimental
Result(s) |
The combination of mTOR dual inhibition by Torin 2 and metformin is associated with an altered metabolomic profile and a significant reduction in pancreatic tumor burden compared with single-agent therapy, and it is better tolerated. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | The Synergistic Effect of an ATP-Competitive Inhibitor of mTOR and Metformin on Pancreatic Tumor Growth. Curr Dev Nutr. 2020 Aug 10;4(9):nzaa131. | |||
